News


All series


All News

According to new findings, tumor mutational burden showed promise as a predictive biomarker for survival benefit in patients with advanced non–small cell lung cancer (NSCLC) treated with the PD-L1 inhibitor durvalumab (Imfinzi) as initial therapy versus chemotherapy, even though there was no difference seen between the 2 treatment groups in the primary analysis of the randomized trial.

Benjamin P. Levy, MD, recently discussed the treatment considerations and decisions he makes when treating patients with non–small cell lung cancer. Levy, the clinical director of medical oncology and associate professor of oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, revealed his treatment decisions to the group based on 2 case scenarios of patients with NSCLC that does not have a genetic driver.

A new task force has been created by the American Society of Clinical Oncology to address the disparities that patients with cancer treated in a rural setting face. The “Rural Cancer Care Task Force” will work to close the gap of cancer care between academic and rural settings and improve the outcomes of patients and survivors living in a rural setting.

Erdafitinib (Balversa) has been granted an accelerated approval by the FDA as a treatment for&nbsp;adult patients with locally advanced or metastatic bladder cancer with an <em>FGFR3</em> or <em>FGFR2</em> alteration that has progressed on platinum-containing chemotherapy, making it the first targeted agent to receive approval for&nbsp;metastatic bladder cancer.

The approval for&nbsp;pembrolizumab (Keytruda) has been expanded to include the&nbsp;frontline treatment of patients with stage III non&ndash;small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression level of &ge;1% and do not harbor <em>EGFR</em> or <em>ALK</em> aberrations.

Combining&nbsp;osimertinib with the MET inhibitor&nbsp;savolitinib demonstrated encouraging antitumor activity and an acceptable safety profile in&nbsp;patients with <em>EGFR</em>-mutant, <em>MET</em>-amplified non&ndash;small cell lung cancer who previously received EGFR TKIs, suggesting the regimen could be successful in overcoming <em>MET</em>-driven resistance.